Decoria FillerDecoria Filler
  • HOME
  • BOHUS BIOTECH
  • PRODUCTS
  • REPORTS
  • CONTACT
  • en
    • it

BOHUS BIOTECH

The Decoria manufacturers

Home BOHUS BIOTECH
Bohus Biotech logo

Bohus BioTech AB is a Swedish biotechnology company with a long history of developing and manufacturing hyaluronic acid raw material and products. We are specialized in research, development and manufacturing of high-quality hyaluronic acid and medical device products based on this substance. Our products are sold via a network of distributors in numerous markets around the world.

Bohus BioTech AB was founded in 1992 by the president and majority shareholder, Daniel C. Ogbonnaya, who previously worked as a researcher at Pharmacia for several years. Since 1992 the company has evolved steadily over the years and we are now renowned world-wide for developing and manufacturing quality hyaluronic acid based products.

Bohus BioTech is located in Strömstad on the west coast of Sweden. All of our products are developed and manufactured at our modern production facilities.

Our mission is to manufacture safe, effective and reliable hyaluronic acid based products that will help people to improve their quality of life.

Bohus BioTech office
Bohus biotech
Bohus biotech

Decoria is manufactured by Bohus BioTech in Strömstad, Sweden.

A company with more than 20 years experience of developing and manufacturing products based on hyaluronic acid. Decoria is the result of many years of research and development, as well as product evaluation in close cooperation with clinics. The unique manufacturing process behind Decoria provides a product that, with a low degree of cross linking agent, has a long lasting duration in the skin.

At Bohus BioTech we have a modern production facility of 3,500 m2
that was completed in 2003 and where all products are manufactured.

The facility is designed in accordance with ISO 14644.

Qualified cleanroom staff work in our manufacturing department which is certified to a maximum of ISO class 5. All personell working in the clean room are trained regularly in order to provide the highest level of efficacy and safety within our manufacturing process.
bohus-biotech-3Bohus biotechBohus biotechbohus-biotech-5bohus-biotech-6bohus-biotech-7
Our state-of-the-art equipment, including filling and assembly machines, means that we can handle the products efficiently and safely.
bohus-biotech-decoria

Brief history of Hyaluronic Acid (HA), Bohus BioTech and HA dermal fillers

1934

Scientists Karl Meyer and John Palmer at Columbia University, New York, discover hyaluronic acid

1942

First commercial use of hyaluronic acid as egg white substitute in baking patented by Endre Balazs

1943

First use of hyaluronic acid for medicinal practice in bandages during Second World War

1951

First significant data about the structure of hyaluronic acid published by Ogston and Stanier

1970

Hyaluronic acid first injected into the joints of racehorses suffering from arthritis with positive results, leading to Hylartil (precursor to Healon), the first commercial medical product based on hyaluronic acid

1980

Extensive research into the usage of hyaluronic acid during cataract surgery leads to the launch of Healon by Pharmacia

1992

Bohus BioTech starts its operations in Strömstad, Sweden. The founder, Daniel C. Ogbonnaya, is a former scientist from Pharmacia.

1994

Bohus BioTech launches its first hyaluronic acid-based product, Microvisc, used in cataract surgery

The first clinical trial for Q-Plast (pilot version of Restylane) is performed

1995

Biomatrix obtains CE-mark for Hylaform

Q-Med files the NASHA patent application

1996

Collagen Inc. launches Hylaform on the European market

Q-Med obtains CE-mark for Restylane and launches the product shortly after Collagen’s launch of Hylaform

2000

Corneal obtains CE-mark for Juvéderm

2002

Allergan obtains FDA-approval for Botox Cosmetic

2003

Q-Med obtains FDA-approval for Restylane

Former Corneal alumnis found Anteis, the company behind Esthelís

Q-Med signs license agreement with Medicis for Restylane and Perlane on the North American market

2004

Hylaform approved by FDA

2006

Juvéderm approved by FDA

Allergan buys Corneal, including Juvéderm

2011

Belotero Balance, produced by Anteis and sold by Merz on the U.S. market, approved by FDA

Juvéderm, according to Allergan, has captured position as the world’s No.1 selling dermal filler brand - Swiss Galderma buys Q-Med for 1.22 billion US$- Sanofi buys Genzyme Corp.

2012

Valeant buys Medicis

2013

Anteis acquired by Merz

2014

Galderma reclaims U.S. sales rights for various products, incl. Restylane and Perlane from Valeant

Bohus BioTech launches Decoria after two years of development

Actavis plc. Acquires Allergan, incl. Juvéderm, for 66 billion US$

  • PRIVACY POLICY
© Bohus BioTech AB